Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
562.27
+1.52 (0.27%)
At close: Sep 30, 2025, 4:00 PM EDT
564.19
+1.92 (0.34%)
After-hours: Sep 30, 2025, 5:53 PM EDT
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.68B in the quarter ending June 30, 2025, with 3.62% growth. This brings the company's revenue in the last twelve months to $14.21B, up 5.38% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.21B
Revenue Growth
+5.38%
P/S Ratio
4.23
Revenue / Employee
$940,964
Employees
15,106
Market Cap
58.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
REGN News
- 1 hour ago - Regeneron: Growth Catalysts Incoming - Seeking Alpha
- 2 hours ago - Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 - GlobeNewsWire
- 3 days ago - Regeneron: Strong R&D Pipeline Drives Growth Outlook - Seeking Alpha
- 4 days ago - Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol - GlobeNewsWire
- 6 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript - Seeking Alpha
- 6 days ago - Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises - Seeking Alpha
- 8 days ago - Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion - GlobeNewsWire
- 8 days ago - Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion - GlobeNewsWire